Loading...

Home
ETF
ANAB

ANAB

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ANAB News

AnaptysBio Q1 Earnings Report Analysis

May 12 2026seekingalpha

AnaptysBio Strengthens Leadership Team and Board

May 11 2026Newsfilter

Vanda Pharmaceuticals Publishes Imsidolimab Research Findings

Apr 28 2026PRnewswire

Vanda Pharmaceuticals Announces Imsidolimab Research Findings

Apr 28 2026Newsfilter

Tesaro and AnaptysBio Litigation Update

Apr 27 2026seekingalpha

Delaware Court Dismisses AnaptysBio's Claim Against TESARO

Apr 27 2026seekingalpha

GSK and Tesaro Assert That Allegations Lack Merit and Are Committed to Defending Their Case in Court

Apr 27 2026moomoo

AnaptysBio Completes Spinoff of First Tracks Biotherapeutics

Apr 20 2026seekingalpha

AnaptysBio Completes Spin-Off, Focuses on Royalty Management

Apr 20 2026Newsfilter

ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS

Apr 20 2026moomoo

AnaptysBio Approves Spin-Off of First Tracks Biotherapeutics

Mar 27 2026seekingalpha

AnaptysBio Announces $100 Million Buyback and Business Update

Mar 27 2026NASDAQ.COM

Anaptys Announces Spin-Off of Biopharma Operations

Mar 27 2026Newsfilter

First Tracks Biotherapeutics Secures $145 Million in Private Placement Financing

Mar 27 2026Newsfilter

First Tracks Biotherapeutics Spin-Off Date Set

Mar 27 2026Newsfilter

ANAPTYSBIO INC - AJIM TAMBOLI LIKELY TO BE NAMED CFO OF FIRST TRACKS BIO

Mar 27 2026moomoo